Biologics for chronic rhinosinusitis with nasal polyps

Area of Science:

• Immunology
• Otolaryngology
• Pharmacology

Background:

• Type 2 immune responses are increasingly recognized in chronic rhinosinusitis (CRS) severity, recurrence, and comorbidities.
• Previous small studies explored biologics targeting IL-4, IL-5, IL-13, and IgE for CRS with nasal polyps (CRSwNP).

Purpose of the Study:

• To evaluate the efficacy and clinical impact of dupilumab, an IL-4 receptor antagonist, in patients with moderate-to-severe chronic rhinosinusitis with nasal polyps.
• To assess the effect of dupilumab on disease burden, symptoms, quality of life, and need for concomitant treatments like systemic glucocorticosteroids and surgery.

Main Methods:

• Phase 3 clinical trials were conducted to assess dupilumab's efficacy in CRSwNP.
• Key outcome measures included polyp size, sinus involvement, symptom scores, sense of smell, quality of life, and the reduction in systemic steroid and surgical interventions compared to placebo.

Main Results:

• Dupilumab demonstrated a significant and clinically relevant reduction in disease burden, including polyp size and sinus involvement.
• Patients treated with dupilumab experienced significant improvements in symptoms, smell, and quality of life.
• The biologic treatment led to a significant and meaningful decrease in the need for systemic glucocorticosteroids and sinus surgery.

Conclusions:

• Dupilumab is a registered and effective treatment for chronic rhinosinusitis with nasal polyps in Europe and the United States.
• The findings indicate a new therapeutic era for severe, uncontrolled CRSwNP, with biologics offering significant benefits.
• Further research is needed to establish clear indications, patient selection criteria, and monitoring protocols for biologics in CRSwNP care pathways.